Esperion Therapeutics (ESPR) Total Non-Current Liabilities (2012 - 2026)

Esperion Therapeutics has reported Total Non-Current Liabilities for 10 years, with the latest figure at $761.7 million in Q1 2026.

• For the quarter ending Q1 2026, Total Non-Current Liabilities changed N/A year-over-year to $761.7 million; the trailing twelve-month figure through Mar 2026 stood at $761.7 million (changed N/A YoY), and the FY2025 full-year result was $759.1 million, up 3.63% from the prior year.
• Total Non-Current Liabilities for Q1 2026 stood at $761.7 million, roughly flat from $759.1 million in the prior quarter.
• The five-year high for Total Non-Current Liabilities was $807.9 million in Q3 2025, with the low at $338.4 million in Q1 2022.
• Historically, Total Non-Current Liabilities has averaged $535.6 million across 5 years, with a median of $425.9 million in 2023.
• Annual changes were most pronounced in 2022 — Total Non-Current Liabilities plunged 41.44% — and 2024, when it soared 88.45%.
• Esperion Therapeutics' Total Non-Current Liabilities stood at $352.9 million in 2022, then gained by 19.26% to $420.8 million in 2023, then soared by 74.07% to $732.5 million in 2024, then rose by 3.63% to $759.1 million in 2025, then gained by 0.34% to $761.7 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $761.7 million (Q1 2026), $759.1 million (Q4 2025), and $807.9 million (Q3 2025), per Business Quant data.